Johnson & Johnson expands in Hong Kong market with support

Leading multinational healthcare company Johnson & Johnson announced on Mar 14 that it has appointed DKSH Business Unit Healthcare, a leading market expansion services provider for healthcare companies seeking to grow their business in Asia, to grow its consumer health business in Hong Kong.

Greater support in market expansion

Under the agreement, a dedicated DKSH Business Unit Healthcare team will provide marketing, sales, distribution and logistics support to Johnson & Johnson in both retail as well as professional healthcare channels such as hospitals, clinics, pharmacies, or even physicians all over Hong Kong.

The new partnership between Johnson & Johnson and DKSH Business Unit Healthcare follows an earlier announcement in which DKSH had been appointed by Procter & Gamble, the multinational consumer goods company, to sell and distribute their brands in Hong Kong. These agreements are also evidence that in more complex market conditions, clients increasingly tend to outsource parts of the value chain to market expansion service providers such as DKSH.

More than 20 brands of consumer health products

The broad range of Johnson & Johnson’s brands of products under the agreement include Regaine, Listerine, Aveeno, Neutrogena, Anusol, Gelusil, Imodium, Nicorette, Nizoral, Pregaine, Trosyd, Bandaid and Carefree, as well as Johnson's Baby. In total, DKSH will look after more than 20 brands of over-the-counter (OTC) and consumer health products from Johnson & Johnson.

"The fact that a major healthcare company like Johnson & Johnson outsources a significant part of the business to DKSH underlines our strong position in the Asian market. Our direct reach, dedication to marketing and sales, as well as our unique capillary distribution, make us the leading partner for growth," said Grace Lau, vice-president, Business Unit Healthcare, DKSH Hong Kong.

“The trust from the client to grow its business in Hong Kong is a big boost for us to outperform in the market,” she added.

DKSH is a publicly listed company on the SIX Swiss Exchange, headquartered in Zurich. DKSH Business Unit Healthcare’s custom offerings comprise registration, regulatory services, market entry studies, importation, customs clearance, marketing and sales, capillary physical distribution, invoicing and cash collection. Products available through it include pharmaceuticals, consumer health and OTC products as well as medical devices.